With ongoing growth across the board, plan sponsors are continuously searching for ways to minimize the impact on their bottom line.
Lee Feigert, PharmD, MSPBA
Advertisement
Articles by Lee Feigert, PharmD, MSPBA
There are currently firms working to use artificial intelligence in hopes that it could contribute to minimizing the impact of the opioid epidemic.
The world is rapidly moving towards the adoption and seamless integration of artificial intelligence (AI), including machine learning as a subset of AI, throughout our daily lives.
Advertisement
Latest Updated Articles
Co-pay Accumulator Programs: Behind the ControversyJuly 22nd 2019
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
3
Building a Pharmacist-Led Furoscix Workflow From Scratch
4
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
5